Eli Lilly (LLY) Deferred Taxes (2009 - 2026)

Eli Lilly (LLY) has 18 years of Deferred Taxes data on file, last reported at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Deferred Taxes rose 277.04% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $2.8 billion (changed 0.11% YoY), and the FY2025 full-year result was $1.7 billion, down 36.38% from the prior year.
• Deferred Taxes for Q1 2026 stood at $1.5 billion, up from $748.1 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $1.5 billion in Q1 2026 and bottomed at -$501.4 million in Q3 2025.
• The 5-year median for Deferred Taxes is $559.4 million (2023), against an average of $611.4 million.
• The widest annual swing landed in 2023, when Deferred Taxes soared 4967.31%; it then tumbled 216.66% in 2025.
• A 5-year view of Deferred Taxes shows it stood at -$10.4 million in 2022, then jumped by 4967.31% to $506.2 million in 2023, then surged by 90.95% to $966.6 million in 2024, then fell by 22.61% to $748.1 million in 2025, then soared by 97.57% to $1.5 billion in 2026.
• The last three Deferred Taxes figures came in at $1.5 billion (Q1 2026), $748.1 million (Q4 2025), and -$501.4 million (Q3 2025), per Business Quant data.

Peer Comparison